COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

GOG-3059 - A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer

Protocol No
GOG-3059-AVB500-OC-004
Principal Investigator
Elizabeth Hopp
Phase
III
Summary
The purpose of this research study is to evaluate the safety and efficacy of AVB-S6-500 combined with PAC in subjects with platinum-resistant, recurrent ovarian cancer.
Description
The purpose of this research study is to evaluate the safety and efficacy of AVB-S6-500
combined with PAC in subjects with platinum-resistant, recurrent ovarian cancer.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category